Muriel P, Castro V
Departamento de Farmacología y Toxicología, Centro de Investigación y de Estudios Avanzados del IPN, México, D.F., Mexico.
Pharmacology. 1997 Apr;54(4):179-85. doi: 10.1159/000139485.
Interferons have been utilized widely in chronic liver diseases for their antiviral properties. In addition, there is evidence for their antifibrogenic actions. In this work we studied effects of various doses of interferon-alpha 2b on experimental liver fibrosis and cholestasis induced in the rat by biliary obstruction. Collagen was measured as hepatic hydroxyproline content. Cholestasis was determined by serum alkaline phosphatase and gamma-glutamyltranspeptidase activities and by bilirubin content. Glycogen was measured in the liver. Interestingly, the best effects (antifibrotic and anticholestatic) were observed in the group receiving the lowest dose of interferon. These results suggest that interferon-alpha 2b may be used at low doses, thereby decreasing side effects and costs.
干扰素因其抗病毒特性已被广泛应用于慢性肝病。此外，有证据表明其具有抗纤维化作用。在这项研究中，我们研究了不同剂量的干扰素α-2b对大鼠胆管阻塞诱导的实验性肝纤维化和胆汁淤积的影响。胶原蛋白以肝脏羟脯氨酸含量来衡量。胆汁淤积通过血清碱性磷酸酶和γ-谷氨酰转肽酶活性以及胆红素含量来确定。肝脏中糖原的含量也进行了测定。有趣的是，在接受最低剂量干扰素的组中观察到了最佳效果（抗纤维化和抗胆汁淤积）。这些结果表明，干扰素α-2b可以低剂量使用，从而降低副作用和成本。
